Autologous Cell Therapy Market Report 2026

The autologous cell therapy market size has grown rapidly in recent years. It will grow from $12.14 billion in 2025 to $14.28 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to advancements in stem cell research, early clinical success of autologous therapies, increasing prevalence of chronic diseases, expansion of oncology treatment options, rising investments in regenerative medicine.

The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $27.31 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to increasing approvals of cell-based therapies, growing demand for personalized medicine, expansion of manufacturing automation in cell therapy, rising clinical trial activity, increasing healthcare spending on advanced therapies. Major trends in the forecast period include increasing adoption of car t-cell therapies, rising use of personalized regenerative treatments, growing integration of automated cell processing systems, expansion of autologous stem cell applications, enhanced focus on patient-specific therapeutic outcomes.

The rising prevalence of chronic diseases is anticipated to propel the growth of autologous cell therapy. Chronic disease refers to a condition or illness that persists for more than a year and requires continuous medical care. Autologous cell therapy provides a promising method for treating and managing these conditions by using a person’s own cells, which are expanded and cultivated outside the body before being reintroduced into the donor. For example, in January 2023, according to the National Library of Medicine, a US-based organization, the number of people in the US aged 50 and above with at least one chronic condition is projected to reach 142.66 million by 2050. Therefore, the high prevalence of chronic diseases is fueling the growth of the autologous cell therapy market.

Major companies are active in the autologous cell therapy market, concentrating on developing technological innovations such as robotic, end-to-end manufacturing platforms for patient-specific therapies to enhance process consistency, lower contamination risk, and shorten time-to-patient. An end-to-end manufacturing platform combines multiple cell-processing steps, including isolation, activation, transduction, expansion, formulation, and harvest within a single closed system, reducing manual handling compared to traditional open flask- or bag-based approaches. For example, in April 2025, Cellares, a US-based integrated development and manufacturing organization, introduced the Cell Shuttle system for autologous cell therapies. The system automates the entire workflow in a functionally closed cassette, improves reproducibility, minimizes contamination risk, and facilitates scalable, patient-specific manufacturing, supporting faster development and delivery of personalized therapies.

In October 2023, Clade Therapeutics, a US-based cell therapy company, acquired Gadeta B.V. for an undisclosed sum. This acquisition expands Clade’s portfolio by adding cell therapies, including innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. Gadeta B.V. is a Netherlands-based cell therapy company.

Major companies operating in the autologous cell therapy market are Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Vericel Corporation, Dendreon Pharmaceuticals LLC, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Castle Creek Biosciences Inc., Pharmicell Co. Ltd., Medipost Co. Ltd., Tego Science AB, Holostem Terapie Avanzate S.r.l., Opexa Therapeutics Inc., CORESTEM Inc., Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Autolus Therapeutics plc.

North America was the largest region in the autologous cell therapy market in 2025.Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autologous cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the autologous cell therapy market by increasing costs of imported bioprocessing equipment, single-use consumables, cell culture media, and advanced laboratory instruments required for cell collection, processing, and reinfusion. North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces higher costs in scaling clinical manufacturing facilities. These tariffs are raising therapy development costs and extending commercialization timelines. However, they are also encouraging domestic manufacturing of cell therapy tools, localized supply chains, and regional innovation hubs supporting long-term market growth.

The autologous cell therapy market research report is one of a series of new reports that provides autologous cell therapy market statistics, including autologous cell therapy industry global market size, regional shares, competitors with a autologous cell therapy market share, detailed autologous cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous cell therapy industry. This autologous cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Autologous cell therapy is a form of cell therapy in which a patient's own cells are collected, processed, and then reintroduced into their body for treatment purposes. It is commonly applied in regenerative medicine to repair, replace, or restore damaged tissues or organs.

The main types of autologous cell therapy include autologous stem cell therapy and autologous cellular immunotherapies. Autologous stem cell therapy is a specific type of autologous cell therapy that uses stem cells obtained from the patient’s own body for treatment purposes. These stem cells can be sourced from bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, and others, and are applied in the treatment of cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and more. This therapy is utilized by hospitals and clinics, ambulatory centers, academic and research institutions, and other healthcare providers.

The autologous cell therapy market includes revenues earned by providing services in relation to cell collection, cell processing, cell expansion, or its modification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.